A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: Extension and analysis of a previously reported cohort of patients

European Journal of Surgical Oncology

Volumn 39, Issue 10, 2013, Pages 1046-1052

  Miglietta, L ^a   Morabito, F ^b   Provinciali, N ^c   Canobbio, L ^c   Meszaros, P ^a   Naso, C ^d   Murialdo, R ^e   Boitano, M ^c   Salvi, S ^a   Ferrarini, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Azienda Ospedaliera Annunziata   (Italy)

^c Ist Naz Ric sul Cancro di Genova   (Italy)

^d SANTA CORONA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Estrogen receptor; Immunohistochemical score; Ki 67; Locally advanced breast cancer; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME;

ESTROGEN RECEPTOR; IMMUNOHISTOCHEMICAL SCORE; KI-67; LOCALLY ADVANCED BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84884904172     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.06.024     Document Type: Article

References (23)

1. L. Miglietta, P. Vanella, and L. Canobbio Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis Oncology 79 2010 255 261
2. R.L. Jones, J. Salter, and R. A'Hern Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer Breast Cancer Res Treat 119 2010 315 323
3. M. Kaufmann, G. von Minckwitz, and H.D. Bear Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 18 2007 1927 1934
4. T. Tanei, A. Shimomura, and K. Shimazu Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer Eur J Surg Oncol 37 2011 155 161
5. M. Colleoni, V. Bagnardi, and N. Rotmensz A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer Ann Oncol 20 2009 1178 1184
6. V. Guarneri, K. Broglio, and S.W. Kau Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044
7. T. Petit, M. Wilt, and M. Velten Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer Breast Cancer Res Treat 124 2010 387 391
8. M. Colleoni, I. Minchella, and G. Mazzarol Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors Ann Oncol 11 2000 1057 1059
9. R. Yerushalmi, R. Woods, P.M. Ravdin, M.M. Hayes, and K.A. Gelmon Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 2010 174 183
10. M. Dowsett, I.E. Smith, and S.R. Ebbs Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival Clin Cancer Res 11 2005 951s 958s
11. J. Lee, Y.H. Im, and S.H. Lee Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Cancer Chemother Pharmacol 61 2008 569 577
12. E. de Azambuja, F. Cardoso, and G. de Castro Jr. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 2007 1504 1513
13. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
14. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 221
15. E.W. Steyerberg Clinical prediction model. A practical approach to development, validation and updating 2009 Springer Edition New York 94 96
16. V. Guarneri, F. Piacentini, and G. Ficarra A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann Oncol 20 2009 1193 1198
17. H. Cure, S. Amat, and F. Penault-Llorca Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy Breast Cancer Res Treat 76 2002 37 45
18. E. Thomas, F.A. Holmes, and T.L. Smith The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial J Clin Oncol 22 2004 2294 2302
19. R.L. Jones, and I.E. Smith Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response Lancet Oncol 7 2006 869 874
20. M. Dowsett, T.O. Nielsen, and R. A'Hern Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group J Natl Cancer Inst 103 2011 1656 1664
21. M.J. Ellis, W.R. Miller, and Y. Tao Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial Breast Cancer Res Treat 116 2008 371 378
22. R.L. Jones, J. Salter, and R. A'Hern The prognostic significance ok Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 2009 53 68
23. S. van de Ven, V.T. Smit, T.J. Dekker, J.W. Nortier, and J.R. Kroep Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer Cancer Treat Rev 37 2011 422 430